Invention Grant
- Patent Title: Antibodies against TL1a and uses thereof
-
Application No.: US15206493Application Date: 2016-07-11
-
Publication No.: US10822422B2Publication Date: 2020-11-03
- Inventor: Lynn Dorothy Poulton , Adam Clarke , Andrew James Pow , Debra Tamvakis , George Kopsidas , Anthony Gerard Doyle , Philip Anthony Jennings , Matthew Pollard
- Applicant: Teva Pharmaceuticals Australia Pty Ltd
- Applicant Address: AU Macquarie Park
- Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee: Teva Pharmaceuticals Australia Pty Ltd
- Current Assignee Address: AU Macquarie Park
- Agency: Sterne, Kessler, Goldstein & Fox P.L.L.C.
- Priority: com.zzzhc.datahub.patent.etl.us.BibliographicData$PriorityClaim@5f35a112
- Main IPC: C07K16/24
- IPC: C07K16/24 ; C07K16/28 ; G01N33/68 ; A61K39/00
Abstract:
The disclosure provides TNF-like ligand 1a (TL1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to TL1a and inhibits interaction of TL1a and Death Receptor 3 (DR3) and which does not inhibit the interaction of TL1a and Decoy Receptor 3 (DcR3). The disclosure also provides uses of the TL1a-binding proteins.
Public/Granted literature
- US20160333104A1 Antibodies Against TL1a and Uses Thereof Public/Granted day:2016-11-17
Information query
